Bluejay completes SYMON-II enrollment of 750 patients; cash $9.6M, runway to Q2 2027

Bluejay Diagnostics, Inc.

Completed targeted enrollment of 750 patients in SYMON-II pivotal study for Symphony IL-6 test.
Cash and equivalents $9.6M at June 30, 2026 vs $5.2M at Dec 31, 2025; net proceeds $7.6M from June 2026 private placement.
Signed US manufacturing contract to mitigate supply-chain risk; advancing toward FDA 510(k) submission.
Cash estimated to fund operations through Q2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.